Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Gross Margin (2018 - 2025)

Dna X (SONM) has disclosed Gross Margin for 8 consecutive years, with 11.2% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 1697.0% year-over-year to 11.2%, compared with a TTM value of 16.23% through Sep 2025, down 1060.0%, and an annual FY2024 reading of 17.02%, down 362.0% over the prior year.
  • Gross Margin was 11.2% for Q3 2025 at Dna X, up from 7.55% in the prior quarter.
  • Across five years, Gross Margin topped out at 49.97% in Q1 2025 and bottomed at 3.06% in Q4 2021.
  • Average Gross Margin over 5 years is 18.41%, with a median of 16.49% recorded in 2023.
  • The sharpest move saw Gross Margin crashed -3893bps in 2024, then skyrocketed 3267bps in 2025.
  • Year by year, Gross Margin stood at 3.06% in 2021, then skyrocketed by 633bps to 16.3% in 2022, then soared by 134bps to 38.12% in 2023, then tumbled by -102bps to 0.81% in 2024, then surged by 1486bps to 11.2% in 2025.
  • Business Quant data shows Gross Margin for SONM at 11.2% in Q3 2025, 7.55% in Q2 2025, and 49.97% in Q1 2025.